VSTM vs. CRDF

Last updated Apr 1, 2026

Compare and contrast key facts about Verastem, Inc. (VSTM) and Cardiff Oncology, Inc. (CRDF).

Performance

VSTM vs. CRDF - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Verastem, Inc. (VSTM) and Cardiff Oncology, Inc. (CRDF). The values are adjusted to include any dividend payments, if applicable.

VSTM vs. CRDF - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
VSTM Verastem, Inc.	-31.35%	49.32%	-36.49%	68.53%	-80.37%	-3.76%	58.96%	-60.12%	9.45%	174.11%
CRDF Cardiff Oncology, Inc.	-42.35%	-35.25%	193.24%	5.71%	-76.71%	-66.59%	1,350.81%	-60.67%	-85.76%	-85.36%

Fundamentals

EPS VSTM : -$3.28 CRDF : -$0.69
PS Ratio VSTM : 29.15 CRDF : 235.58
Total Revenue (TTM) VSTM : $13.38M CRDF : $459.00K
Gross Profit (TTM) VSTM : $11.26M CRDF : -$11.12M
EBITDA (TTM) VSTM : -$238.93M CRDF : -$47.20M

Returns By Period

In the year-to-date period, VSTM achieves a -31.35% return, which is significantly higher than CRDF's -42.35% return. Over the past 10 years, VSTM has outperformed CRDF with an annualized return of -11.97%, while CRDF has yielded a comparatively lower -41.52% annualized return.

VSTM

• 1D: 9.28%
• 1M: -7.34%
• YTD: -31.35%
• 6M: -39.98%
• 1Y: -12.11%
• 3Y*: 2.08%
• 5Y*: -30.06%
• 10Y*: -11.97%

CRDF

• 1D: 4.52%
• 1M: -16.49%
• YTD: -42.35%
• 6M: -21.36%
• 1Y: -48.41%
• 3Y*: -0.61%
• 5Y*: -30.00%
• 10Y*: -41.52%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

VSTM vs. CRDF — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VSTM

VSTM Risk / Return Rank: 36
VSTM Sharpe Ratio Rank: 35
VSTM Sortino Ratio Rank: 40
VSTM Omega Ratio Rank: 39
VSTM Calmar Ratio Rank: 33
VSTM Martin Ratio Rank: 34

CRDF

CRDF Risk / Return Rank: 18
CRDF Sharpe Ratio Rank: 16
CRDF Sortino Ratio Rank: 20
CRDF Omega Ratio Rank: 20
CRDF Calmar Ratio Rank: 14
CRDF Martin Ratio Rank: 19

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VSTM vs. CRDF - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Verastem, Inc. (VSTM) and Cardiff Oncology, Inc. (CRDF). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	VSTM	CRDF	Difference
Sharpe ratio Return per unit of total volatility	-0.14	-0.58	+0.44
Sortino ratio Return per unit of downside risk	0.41	-0.46	+0.87
Omega ratio Gain probability vs. loss probability	1.05	0.94	+0.11
Calmar ratio Return relative to maximum drawdown	-0.26	-0.76	+0.50
Martin ratio Return relative to average drawdown	-0.49	-1.19	+0.69
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

VSTM vs. CRDF - Sharpe Ratio Comparison

The current VSTM Sharpe Ratio is -0.14, which is higher than the CRDF Sharpe Ratio of -0.58. The chart below compares the historical Sharpe Ratios of VSTM and CRDF, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	VSTM	CRDF	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.14	-0.58	+0.44
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.29	-0.30	+0.02
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.12	-0.39	+0.27
Sharpe Ratio (All Time) Calculated using the full available price history	-0.23	-0.23	0.00

Correlation

The correlation between VSTM and CRDF is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

VSTM vs. CRDF - Dividend Comparison

Neither VSTM nor CRDF has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

VSTM vs. CRDF - Drawdown Comparison

The maximum VSTM drawdown since its inception was -98.96%, roughly equal to the maximum CRDF drawdown of -99.96%. Use the drawdown chart below to compare losses from any high point for VSTM and CRDF.

Drawdown Indicators

	VSTM	CRDF	Difference
Max Drawdown Largest peak-to-trough decline	-98.96%	-99.96%	+1.00%
Max Drawdown (1Y) Largest decline over 1 year	-54.97%	-66.74%	+11.77%
Max Drawdown (5Y) Largest decline over 5 years	-96.22%	-90.44%	-5.78%
Max Drawdown (10Y) Largest decline over 10 years	-98.16%	-99.84%	+1.68%
Current Drawdown Current decline from peak	-97.49%	-99.92%	+2.43%
Average Drawdown Average peak-to-trough decline	-74.99%	-86.06%	+11.07%
Ulcer Index Depth and duration of drawdowns from previous peaks	29.13%	42.77%	-13.64%

Volatility

VSTM vs. CRDF - Volatility Comparison

Verastem, Inc. (VSTM) has a higher volatility of 20.91% compared to Cardiff Oncology, Inc. (CRDF) at 16.29%. This indicates that VSTM's price experiences larger fluctuations and is considered to be riskier than CRDF based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	VSTM	CRDF	Difference
Volatility (1M) Calculated over the trailing 1-month period	20.91%	16.29%	+4.62%
Volatility (6M) Calculated over the trailing 6-month period	55.68%	63.44%	-7.76%
Volatility (1Y) Calculated over the trailing 1-year period	85.73%	83.87%	+1.86%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	105.90%	99.20%	+6.70%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	97.39%	105.89%	-8.50%

Financials